Last updated on May 2018

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for participants with advanced/metastatic renal cell carcinoma (mRCC). The primary hypotheses of this study are: 1) The combination therapy of pembrolizumab plus axitinib is superior to sunitinib monotherapy with respect to Progression-Free Survival (PFS) as assessed by blinded independent central imaging review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and 2) the combination therapy of pembrolizumab plus axitinib is superior to sunitinib monotherapy with respect to Overall Survival (OS).

Clinical Study Identifier: NCT02853331

Contact Investigators or Research Sites near you

Start Over

Toll Free Number

Call for Information (Investigational Site 0092)
Tucson, AZ United States

Toll Free Number

Call for Information (Investigational Site 0086)
Orange, CA United States

Toll Free Number

Call for Information (Investigational Site 8001)
Denver, CO United States

Toll Free Number

Call for Information (Investigational Site 0095)
Washington, D.C., United States

Toll Free Number

Call for Information (Investigational Site 0091)
Marietta, GA United States

Toll Free Number

Call for Information (Investigational Site 0078)
Chicago, IL United States

Toll Free Number

Call for Information (Investigational Site 0041)
Chicago, IL United States

Toll Free Number

Call for Information (Investigational Site 0035)
New Orleans, LA United States

Toll Free Number

Call for Information (Investigational Site 0046)
Lincoln, NE United States

Toll Free Number

Call for Information (Investigational Site 0088)
Buffalo, NY United States

Toll Free Number

Call for Information (Investigational Site 0032)
New York, NY United States

Toll Free Number

Call for Information (Investigational Site 0020)
Rochester, NY United States

Toll Free Number

Call for Information (Investigational Site 0087)
Charlotte, NC United States

Toll Free Number

Call for Information (Investigational Site 0009)
Cleveland, OH United States

Toll Free Number

Call for Information (Investigational Site 0037)
Portland, OR United States

Toll Free Number

Call for Information (Investigational Site 8010)
Tualatin, OR United States

Toll Free Number

Call for Information (Investigational Site 0093)
Allentown, PA United States

Toll Free Number

Call for Information (Investigational Site 0013)
Philadelphia, PA United States

Toll Free Number

Call for Information (Investigational Site 0062)
Pittsburgh, PA United States

Toll Free Number

Call for Information (Investigational Site 8004)
Charleston, SC United States

Toll Free Number

Call for Information (Investigational Site 0089)
Sioux Falls, SD United States

Toll Free Number

Call for Information (Investigational Site 0090)
Chattanooga, TN United States

Toll Free Number

Call for Information (Investigational Site 0070)
Germantown, TN United States

Toll Free Number

Call for Information (Investigational Site 0064)
Dallas, TX United States

Toll Free Number

Call for Information (Investigational Site 8002)
Houston, TX United States

Toll Free Number

Call for Information (Investigational Site 8003)
San Antonio, TX United States

Toll Free Number

Call for Information (Investigational Site 0072)
Salt Lake City, UT United States

Toll Free Number

Call for Information (Investigational Site 0082)
Fairfax, VA United States

MSD Online

MSD Brasil
Sao Paulo, Brazil

Medical Information Centre Centre d'information ...

Merck Canada
Kirkland, QC Canada

Thomas Johansson

MSD SRO Czech
Prague, Czechia

Dominique Blazy

MSD France
Paris, France

German Medical Information Center

MSD Sharp & Dohme GmbH
Haar, Germany

Szabolcs Barotfi

MSD Pharma Hungary Kft.
Budapest, Hungary

Colm Galligan

MSD Ireland (Human Health) Ltd.
Dublin, Ireland

Japan Call Center

MSD K.K.
Chiyoda-Ku, Tokyo, Japan

Jongho Ahn

MSD Korea LTD
Seoul, Korea, Republic of

Thomas Johansson

MSD Polska Sp. Z o.o.
Warsaw, Poland

Tatiana Serebriakova

Merck Sharp & Dohme IDEA, Inc.
Moscow, Russian Federation

Joaquin Mateos Chacon

Merck Sharp and Dohme de Espana S.A.
Madrid, Spain

I-Hua Su

Merck Sharp & Dohme (I.A.) Corp.
Taipei, Taiwan

Eran Gefen

MSD Ukraine LLC
Kiev, Ukraine

Mark Toms

Merck Sharp & Dohme Ltd.
Hoddesdon, United Kingdom